Collaborators GBDF. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204–56. https://doi.org/10.1016/S0140-6736(24)00685-8.

Article  Google Scholar 

Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396(10267):2019–82. https://doi.org/10.1016/S0140-6736(20)32374-6.

Article  PubMed  Google Scholar 

Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685–95. https://doi.org/10.1038/s41569-023-00877-z.

Article  PubMed  Google Scholar 

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91. https://doi.org/10.1056/NEJMoa0706245.

Article  CAS  PubMed  Google Scholar 

Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018;379(7):633–44. https://doi.org/10.1056/NEJMoa1800256.

Article  PubMed  Google Scholar 

Chait A, Eckel RH, Vrablik M, Zambon A. Lipid-lowering in diabetes: An update. Atherosclerosis. 2024;394:117313. https://doi.org/10.1016/j.atherosclerosis.2023.117313.

Article  CAS  PubMed  Google Scholar 

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140. https://doi.org/10.1093/eurheartj/ehad192.

Article  CAS  PubMed  Google Scholar 

Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30. https://doi.org/10.1093/eurheartj/ehz962.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neppala S, Rajan J, Yang E, DeFronzo RA. Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem? Curr Cardiol Rep. 2024. https://doi.org/10.1007/s11886-024-02055-0.

Article  PubMed  Google Scholar 

Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(Suppl C):C2–12. https://doi.org/10.1093/eurheartj/suw009.

Article  CAS  PubMed  Google Scholar 

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–36. https://doi.org/10.1016/j.jacc.2012.08.1026.

Article  CAS  PubMed  Google Scholar 

Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547–63. https://doi.org/10.1161/CIRCRESAHA.115.306249.

Article  CAS  PubMed  Google Scholar 

Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study. Diabetologia. 2023;66(12):2238–49. https://doi.org/10.1007/s00125-023-06016-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. https://doi.org/10.1056/NEJMoa1001282.

Article  Google Scholar 

Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923–34. https://doi.org/10.1056/NEJMoa2210645.

Article  PubMed  Google Scholar 

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268–80. https://doi.org/10.1001/jama.2020.22258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Packard CJ. Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease. Curr Atheroscler Rep. 2022;24(3):133–42. https://doi.org/10.1007/s11883-022-00994-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen SEJ, Varbo A, Nordestgaard BG, Langsted A. Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms. Clin Chem. 2023;69(10):1132–44. https://doi.org/10.1093/clinchem/hvad094.

Article  PubMed  Google Scholar 

Boren J, Taskinen MR, Bjornson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022;19(9):577–92. https://doi.org/10.1038/s41569-022-00676-y.

Article  CAS  PubMed  Google Scholar 

Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806. https://doi.org/10.1093/eurheartj/ehab551.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–95. https://doi.org/10.1016/j.atherosclerosis.2015.01.039.

Article  CAS  PubMed  Google Scholar 

Taskinen MR, Matikainen N, Bjornson E, Soderlund S, Inkeri J, Hakkarainen A, et al. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy. Diabetologia. 2023;66(12):2307–19. https://doi.org/10.1007/s00125-023-06008-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA)2000.

Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453–60. https://doi.org/10.1172/JCI134165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luciani L, Pedrelli M, Parini P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis. 2024;394:117545. https://doi.org/10.1016/j.atherosclerosis.2024.117545.

Article  CAS  PubMed  Google Scholar 

Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol. 2009;23(6):681–5. https://doi.org/10.1111/j.1472-8206.2009.00739.x.

Article  CAS  PubMed  Google Scholar 

Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35. https://doi